Drug intelligence / Profile preview

CNT102

Development stage: Preclinical
Lead developer: Connext

Overview

CNT102 is a preclinical-stage cancer immunotherapy candidate being developed by CONNEXT. As of early 2024, the specific molecular target, modality (such as small molecule, antibody, or cell therapy), and mechanism of action for CNT102 have not been publicly disclosed by the company. The asset is currently positioned in the nonclinical phase of development, aimed at treating various oncological indications through immunotherapeutic approaches.

Beyond the preview

Go deeper on CNT102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CNT102.

Explore the full profile